187 related articles for article (PubMed ID: 36195655)
1. Analysis of the correlation between Zeste enhancer homolog 2 (EZH2) mRNA expression and the prognosis of mesothelioma patients and immune infiltration.
Fan K; Zhang CL; Zhang BH; Gao MQ; Sun YC
Sci Rep; 2022 Oct; 12(1):16583. PubMed ID: 36195655
[TBL] [Abstract][Full Text] [Related]
2. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
Fan K; Zhang BH; Han D; Sun YC
BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic significance and immune cell infiltration analysis of differentially expressed genes in malignant pleural mesothelioma].
Wang N; Zhao QN; Yuan Q; Zhu BL; Wu W
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Sep; 41(9):641-647. PubMed ID: 37805421
[No Abstract] [Full Text] [Related]
4. High Expression of
Ma GY; Shi S; Sang YZ; Wang P; Zhang ZG
Biomed Res Int; 2023; 2023():6575194. PubMed ID: 37139482
[TBL] [Abstract][Full Text] [Related]
5. The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma.
Wu SY; Xie ZY; Yan LY; Liu XF; Zhang Y; Wang DA; Dong J; Sun HT
BMC Immunol; 2022 Jun; 23(1):28. PubMed ID: 35659256
[TBL] [Abstract][Full Text] [Related]
6. Long Non-coding RNA
Endo I; Amatya VJ; Kushitani K; Nakagiri T; Aoe K; Takeshima Y
Anticancer Res; 2023 Dec; 43(12):5367-5376. PubMed ID: 38030172
[TBL] [Abstract][Full Text] [Related]
7. EZH2 is a potential prognostic predictor of glioma.
Chen YN; Hou SQ; Jiang R; Sun JL; Cheng CD; Qian ZR
J Cell Mol Med; 2021 Jan; 25(2):925-936. PubMed ID: 33277782
[TBL] [Abstract][Full Text] [Related]
8. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
[TBL] [Abstract][Full Text] [Related]
10. EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico Analysis.
Du TQ; Liu R; Zhang Q; Luo H; Liu Z; Sun S; Wang X
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358967
[TBL] [Abstract][Full Text] [Related]
11. EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma.
Guo B; Tan X; Cen H
PLoS One; 2020; 15(11):e0242191. PubMed ID: 33180829
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
Fan K; Zhang CL; Qi YF; Dai X; Birling Y; Tan ZF; Cao F
Biomed Res Int; 2020; 2020():2380124. PubMed ID: 33299862
[TBL] [Abstract][Full Text] [Related]
13. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
Lai J; Yang H; Xu T
BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
[TBL] [Abstract][Full Text] [Related]
14. COL1A1 Is a Potential Prognostic Biomarker and Correlated with Immune Infiltration in Mesothelioma.
Zhang C; Liu S; Wang X; Liu H; Zhou X; Liu H
Biomed Res Int; 2021; 2021():5320941. PubMed ID: 33490271
[TBL] [Abstract][Full Text] [Related]
15. Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.
Nakagawa S; Okabe H; Ouchi M; Tokunaga R; Umezaki N; Higashi T; Kaida T; Arima K; Kitano Y; Kuroki H; Mima K; Nitta H; Imai K; Hashimoto D; Yamashita YI; Chikamoto A; Baba H
HPB (Oxford); 2018 Oct; 20(10):939-948. PubMed ID: 29759640
[TBL] [Abstract][Full Text] [Related]
16. Enhancer of zeste homolog 2 is a negative prognostic biomarker and correlated with immune infiltrates in meningioma.
Zeng J; Sun L; Huang J; Yang X; Hu W
Front Neurosci; 2022; 16():1076530. PubMed ID: 36532284
[TBL] [Abstract][Full Text] [Related]
17. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
Hakim SA; Abou Gabal HH
Pathol Oncol Res; 2021; 27():600073. PubMed ID: 34257556
[No Abstract] [Full Text] [Related]
19. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
20. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
